Novel Therapeutic Approaches for Treating Bipolar Disorder

Bipolar Psychopharmacotherapy: Caring for the Patient: Second Edition

Volumn , Issue , 2011, Pages 423-445

  Machado Vieira, Rodrigo ^a   Henter, Ioline ^a   Baumann, Jacqueline ^a   Latov, David ^a   Wheeler Castillo, Cristina ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant; Bioenergetics; Bipolar disorder; Glutamatergic; Ketamine; Mood disorders; Novel therapeutics; Purinergic; Riluzole

Indexed keywords

EID: 84885527470     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975114.ch21     Document Type: Chapter

References (178)

1. Aguado, L., San Antonio, A., Perez, L. et al. (1994) Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav. Neural Biol., 61, 271-281.
2. Akhondzadeh, S., Milajerdi, M.R., Amini, H, et al. (2006) Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebocontrolled trial. Bipolar Disord., 8, 485-489.
3. Alaerts, M., Venken, T., Lenaerts, A.S, et al. (2006) Lack of association of an insertion/deletion polymorphism in the G protein-coupled receptor 50 with bipolar disorder in a Northern Swedish population. Psychiatr. Genet., 16, 235-236.
4. Alonso, R., Griebel, G., Pavone, G, et al. (2004) Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol. Psychiatry, 9, 278-286, 24.
5. Andreazza, A.C., Cassini, C., Rosa, A.R, et al. (2007) Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res., 41, 523-529.
6. Andreazza, A.C., Kauer-Sant'anna, M., Frey, B.N, et al. (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord., 111, 135-144.
7. Antoniou, K., Papadopoulou-Daifoti, Z., Hyphantis, T, et al. (2005) A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl.), 183, 154-162.
8. Anumonye, A., Reading, H.W., Knight, F, et al. (1968) Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet, 1, 1290-1293.
9. Armstrong, S.M., McNulty, O.M., Guardiola-Lemaitre, B, et al. (1993) Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav., 46, 45-49.
10. Assis, L.C., Rezin, G.T., Comim, C.M, et al. (2009) Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev. Bras. Psiquiatr., 31, 247-252.
11. Bambico, F.R., Duranti, A., Tontini, A, et al. (2009) Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr. Pharm. Des., 15, 1623-1646.
12. Banasr, M., Chowdhury, G.M., Terwilliger, R, et al. (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry., 15 (5), 501-511.
13. Banasr, M., Soumier, A., Hery, M, et al. (2006) Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry, 59, 1087-1096.
14. Bannerman, D.M., Good, M.A., Butcher, S.P, et al. (1995) Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature, 378, 182-186.
15. Barber, A. and Gottschlich, R. (1997) Novel developments with selective, non-peptidic kappaopioid receptor agonists. Expert. Opin. Investig. Drugs, 6, 1351-1368.
16. Barden, N., Harvey, M., Gagne, B, et al. (2006) Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet., 141B, 374-382.
17. Basso, A.M., Bratcher, N.A., Harris, R.R, et al. (2009) Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav. Brain Res., 198, 83-90.
18. Beaulieu, J.M., Zhang, X., Rodriguiz, R.M, et al. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. U.S.A., 105, 1333-1338.
19. Bebchuk, J.M., Arfken, C.L., Dolan-Manji, S, et al. (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry, 57, 95-97.
20. Belanoff, J.K., Rothschild, A.J., Cassidy, F, et al. (2002) An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry, 52, 386-392.
21. Berk, M., Copolov, D.L., Dean, O, et al. (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol. Psychiatry, 64, 468-475.
22. Berman, R.M., Cappiello, A., Anand, A, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 47, 351-354.
23. Berrocoso, E., Rojas-Corrales, M.O., and Mico, J.A. (2004) Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci. Lett., 363, 25-28.
24. Berrocoso, E., Sanchez-Blazquez, P., Garzon, J, et al. (2009) Opiates as antidepressants. Curr. Pharm. Des., 15, 1612-1622.
25. Bersani, G. and Garavini, A. (2000) Melatonin add-on in manic patients with treatment resistant insomnia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 24, 185-191.
26. Bertaina-Anglade, V., la Rochelle, C.D., Boyer, P.A, et al. (2006) Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol., 17, 703-713.
27. Besson, A., Privat, A.M., Eschalier, A, et al. (1996) Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats. Psychopharmacology (Berl.), 123, 71-78.
28. Black, M.D. (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl.), 179, 154-163.
29. Bleakman, D. and Lodge, D. (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology, 37, 1187-1204.
30. Bodkin, J.A., Zornberg, G.L., Lukas, S.E, et al. (1995) Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol., 15, 49-57.
31. Brown, E.S., Bobadilla, L., and Rush, A.J. (2001) Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord., 3, 23-29.
32. Brown, E.S., Frol, A., Bobadilla, L, et al. (2003) Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids. Psychosomatics, 44, 204-208.
33. Burnstock, G. (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev., 87, 659-797.
34. Calabrese, J.R., Guelfi, J.D., and Perdrizet-Chevallier, C. (2007) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord., 9, 628-635.
35. Carlezon, W.A., Jr., Beguin, C., DiNieri, J.A, et al. (2006) Depressive-like effects of the kappaopioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther., 316, 440-447.
36. Carroll, B.J. and Rubin, R.T. (2008) Mifepristone in psychotic depression? Biol. Psychiatry, 63, e1; author reply e3.
37. Chartoff, E.H., Papadopoulou, M., MacDonald, M.L, et al. (2009) Desipramine reduces stressactivated dynorphin expression and CREB phosphorylation in NAc tissue. Mol. Pharmacol., 75, 704-712.
38. Chen, G., Manji, H.K., Hawver, D.B, et al. (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J. Neurochem., 63, 2361-2364.
39. Cohen, B.M. and Murphy, B. (2008) The effects of pentazocine, a kappa agonist, in patients with mania. Int. J. Neuropsychopharmacol., 11, 243-247.
40. Collingridge, G.L. (1994) Long-term potentiation. A question of reliability. Nature, 371, 652-653. Collingridge, G.L. and Bliss, T.V. (1995) Memories of NMDA receptors and LTP. Trends Neurosci., 18, 54-56.
41. Collingridge, G.L. and Bliss, T.V. (1995) Memories of NMDA receptors and LTP. Trends Neurosci., 18, 54-56.
42. Cryan, J.F., Kelly, P.H., Neijt, H.C, et al. (2003) Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci., 17, 2409-2417.
43. Dableh, L.J., Yashpal, K., Rochford, J, et al. (2005) Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur. J. Pharmacol., 507, 99-105.
44. Darko, D.F., Risch, S.C., Gillin, J.C, et al. (1992) Association of beta-endorphin with specific clinical symptoms of depression. Am. J. Psychiatry, 149, 1162-1167.
45. Devoize, J.L., Rigal, F., Eschalier, A, et al. (1984) Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology (Berl.), 84, 71-75.
46. Du, J., Suzuki, K., Wei, Y, et al. (2007) The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology, 32, 793-802
47. Ducottet, C, Griebel, G., and Belzung, C. (2003) Effects of the selective nonpeptide corticotropinreleasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 625-631.
48. Duman, R.S. and Monteggia, L.M. (2006) A neurotrophic model for stress-related mood disorders. Biol. Psychiatry, 59, 1116-1127.
49. Ebner, K., Sartori, S.B., and Singewald, N. (2009) Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des., 15, 1647-1674.
50. Einat, H., Yuan, P., Szabo, S.T, et al. (2007) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology, 55, 123-131.
51. El Yacoubi, M., Ledent, C., Parmentier, M, et al. (2001) Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br. J. Pharmacol., 134, 68-77.
52. Farrokhi, C., Blanchard, D.C., Griebel, G, et al. (2004) Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. Pharmacol. Biochem. Behav., 77, 465-469.
53. Friedman, E., Hoau Yan, W., Levinson, D, et al. (1993) Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry, 33, 520-525.
54. Frizzo, M.E., Dall'Onder, L.P., Dalcin, K.B, et al. (2004) Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell. Mol. Neurobiol., 24, 123-128.
55. Gallagher, P., Malik, N., Newham, J, et al. (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst. Rev. (DOI number: 10.1002/14651858.CD005168.pub2).
56. Garcia, L.S., Comim, C.M., Valvassori, S.S, et al. (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 140-144.
57. Gasparini, F., Bruno, V., Battaglia, G, et al. (1999) (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther., 289, 1678-1687.
58. Goldstein, J.A. (1986) Danazol and the rapid-cycling patient. J. Clin. Psychiatry, 47, 153-154. Goodwin, F.K. and Jamison, K.R. (2007) Manic-Depressive Illness:Bipolar Disorders and Recurrent Depression, 2nd edn, Oxford University Press, Oxford.
59. Goodwin, F.K. and Jamison, K.R. (2007) Manic-Depressive Illness:Bipolar Disorders and Recurrent Depression, 2nd edn, Oxford University Press, Oxford.
60. Gould, T.D., Einat, H., Bhat, R, et al. (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol., 7, 387-390.
61. Gould, T.D. and Manji, H.K. (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology, 30, 1223-1237.
62. Gould, T.D., Picchini, A.M., Einat, H, et al. (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets, 7, 1399-1409.
63. Griebel, G., Simiand, J., Steinberg, R, et al. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N- [(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2- amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther., 301, 333-345.
64. Grunberg, S.M., Weiss, M.H., Russell, C.A, et al. (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest., 24, 727-733.
65. Hahn, C.G. and Friedman, E. (1999) Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord., 1, 81-86.
66. Hallam, K.T., Olver, J.S., and Norman, T.R. (2005) Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. Aust. N. Z. J. Psychiatry, 39, 947
67. Holmes, A, Heilig, M., Rupniak, N.M, et al. (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci., 24, 580-588.
68. Hurd, Y.L. (2002) Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol. Psychiatry, 7, 75-81.
69. Jahn, H., Schick, M., Kiefer, F, et al. (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch. Gen. Psychiatry, 61, 1235-1244.
70. Jope, R.S. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci., 24, 441-443.
71. Judd, L.L., Akiskal, H.S., Schettler, P.J, et al. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry, 59, 530-537.
72. Jutkiewicz, E.M. (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol. Interv., 6, 162-169.
73. Kaster, M.P., Rosa, A.O., Rosso, M.M, et al. (2004) Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci. Lett., 355, 21-24.
74. Keller, M., Montgomery, S., Ball, W, et al. (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry, 59, 216-223.
75. Kennedy, S.H. and Emsley, R. (2006) Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 16, 93-100.
76. Khairova, R.A., Machado-Vieira, R., Du, J, et al. (2009) A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol., 12, 561-578.
77. Khawaja, A.M. and Rogers, D.F. (1996) Tachykinins: receptor to effector. Int. J. Biochem. Cell. Biol., 28, 721-738.
78. Kinney, G.G., O'Brien, J.A., Lemaire, W, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther., 313, 199-206.
79. Kittner, H., Krugel, U., and Illes, P. (2001) The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. Neuroscience, 102, 241-243.
80. Knapp, R.J., Goldenberg, R., Shuck, C, et al. (2002) Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol., 440, 27-35.
81. Kramer, L., Bauer, E., Funk, G, et al. (2002) Subclinical impairment of brain function in chronic hepatitis C infection. J. Hepatol., 37, 349-354.
82. Kramer, M.S., Cutler, N., Feighner, J, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281, 1640-1645.
83. Kramer, M.S., Winokur, A., Kelsey, J, et al. (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology, 29, 385-392.
84. Kulkarni, J., Garland, K.A., Scaffidi, A, et al. (2006) A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology, 31, 543-547.
85. Kuloglu, M., Ustundag, B., Atmaca, M, et al. (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell. Biochem. Funct., 20, 171-175.
86. Lara, D.R., Dall'Igna, O.P., Ghisolfi, E.S, et al. (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 30, 617-629.
87. Lewy, A.J., Nurnberger, J.I., Jr., Wehr, T.A, et al. (1985) Supersensitivity to light: possible trait marker for manic-depressive illness. Am. J. Psychiatry, 142, 725-727.
88. Lewy, A.J., Wehr, T.A., Goodwin, F.K, et al. (1981) Manic-depressive patients may be supersensitive to light. Lancet, 1, 383-384.
89. Loo, H., Hale, A., and D'Haenen, H. (2002) Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 17, 239-247.
90. Louis, C., Stemmelin, J., Boulay, D, et al. (2008) Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol. Biochem. Behav., 89, 36-45.
91. Lourenco Da Silva, A., Hoffmann, A., Dietrich, M.O, et al. (2003) Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology, 48, 27-30.
92. Lucae, S., Salyakina, D., Barden, N, et al. (2006) P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet., 15, 2438-2445.
93. MacDonald, M.L., Naydenov, A., Chu, M, et al. (2006) Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord., 8, 255-264.
94. Machado-Vieira, R., Andreazza, A.C., Viale, C.I, et al. (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett., 421, 33-36.
95. Machado-Vieira, R., Lara, D.R., Souza, D.O, et al. (2001) Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J. Clin. Psychopharmacol., 21, 621-622.
96. Machado-Vieira, R., Lara, D.R., Souza, D.O, et al. (2002) Purinergic dysfunction in mania: an integrative model. Med. Hypotheses, 58, 297-304.
97. Machado-Vieira, R., Manji, H.K., and Zarate, C.A. (2009) The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist., 15 (5), 525-539.
98. Machado-Vieira, R., Soares, J.C., Lara, D.R, et al. (2008) A double-blind, randomized, placebocontrolled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry, 69, 1237-1245.
99. Maeng, S., Zarate, C.A., Jr., Du, J, et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry, 63, 349-352.
100. Mague, S.D., Pliakas, A.M., Todtenkopf, M.S, et al. (2003) Antidepressant-like effects of kappaopioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther., 305, 323-330.
101. Manji, H.K., Etcheberrigaray, R., Chen, G, et al. (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J. Neurochem., 61, 2303-2310.
102. Manji, H.K. and Lenox, R.H. (1999) Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry, 46, 1328-1351.
103. Manzanares, J., Uriguen, L., Rubio, G, et al. (2004) Role of endocannabinoid system in mental diseases. Neurotox. Res., 6, 213-224
104. Meloni, D, Gambarana, C., De Montis, M.G, et al. (1993) Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol. Biochem. Behav., 46, 423-426.
105. Micale, V., Tamburella, A., Leggio, G.M, et al. (2008) Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stressrelated conditions. Pharmacol. Biochem. Behav., 90, 463-469.
106. Mickley, G.A., Schaldach, M.A., Snyder, K.J, et al. (1998) Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol. Behav., 64, 381-390.
107. Millan, M.J., Brocco, M., Gobert, A, et al. (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl.), 177, 448-458.
108. Mitchell, P.B. and Morris, M.J. (2007) Depression and anxiety with rimonabant. Lancet, 370, 1671-1672.
109. Miu, P., Jarvie, K.R., Radhakrishnan, V, et al. (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology, 40, 976-983.
110. Mizuta, I., Ohta, M., Ohta, K, et al. (2001) Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett., 310, 117-120.
111. Moghaddam, B., Adams, B., Verma, A, et al. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci., 17, 2921-2927.
112. Montgomery, S.A. and Kasper, S. (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol., 22, 283-291.
113. M̈uller, N., Schwarz, M.J., Dehning, S, et al. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry, 11, 680-684.
114. Nagayama, H. (1996) Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Chronobiol. Int., 13, 251-259.
115. Nery, F.G., Monkul, E.S., Hatch, J.P, et al. (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol., 23, 87-94.
116. Nurnberger, J.I., Jr., Adkins, S., Lahiri, D.K, et al. (2000) Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch. Gen. Psychiatry, 57, 572-579.
117. Ogawa, N. and Ueki, H. (2003) Secondary mania caused by caffeine. Gen. Hosp. Psychiatry, 25, 138-139.
118. Padovan, C.M. and Guimaraes, F.S. (2004) Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol. Biochem. Behav., 77, 15-19.
119. Pae, C.U., Marks, D.M., Han, C, et al. (2008) Does minocycline have antidepressant effect? Biomed. Pharmacother., 62, 308-311.
120. Palucha, A. and Pilc, A. (2007) Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther., 115, 116-147.
121. Papp, M., Gruca, P., Boyer, P.A, et al. (2003) Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology, 28, 694-703.
122. Papp, M. and Moryl, E. (1993) New evidence for the antidepressant activity of MK-801, a noncompetitive antagonist of NMDA receptors. Pol. J. Pharmacol., 45, 549-553.
123. Pitkanen, A., Mathiesen, C., Ronn, L.C, et al. (2007) Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res., 74, 45-54
124. Quiroz, JA., Gray, N.A., Kato, T, et al. (2008) Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 33, 2551-2565.
125. Quiroz, J.A., Singh, J., Gould, T.D, et al. (2004) Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol. Psychiatry, 9, 756-776.
126. Ragnauth, A., Schuller, A., Morgan, M, et al. (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc. Natl. Acad. Sci. U.S.A., 98, 1958-1963.
127. Rao, J.S., Bazinet, R.P., Rapoport, S.I, et al. (2007) Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord., 9, 513-520.
128. Rapoport, S.I., Basselin, M., Kim, H.W, et al. (2009) Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res. Rev., 61 (2), 185-209.
129. Rayasam, G.V., Tulasi, V.K., Sodhi, R, et al. (2009) Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol., 156, 885-898.
130. Redman, J.R. and Francis, A.J. (1998) Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J. Biol. Rhythms, 13, 39-51.
131. Reindl, J.D., Rowan, K., Carey, A.N, et al. (2008) Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology, 81, 229-235.
132. Rimoy, G.H., Wright, D.M., Bhaskar, N.K, et al. (1994) The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur. J. Clin. Pharmacol., 46, 203-207.
133. Rogawski, M.A. (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res., 69, 273-294.
134. Roitman, S., Green, T., Osher, Y, et al. (2007) Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disord., 9, 754-758.
135. Rojas-Corrales, M.O., Berrocoso, E., Gibert-Rahola, J, et al. (2002) Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci., 72, 143-152.
136. Rojas-Corrales, M.O., Berrocoso, E., Gibert-Rahola, J, et al. (2004) Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J. Psychopharmacol., 18, 404-411.
137. Rojas-Corrales, M.O., Gibert-Rahola, J., and Mico, J.A. (1998) Tramadol induces antidepressanttype effects in mice. Life Sci., 63, PL175-PL180.
138. Ross, B.M., Brooks, R.J., Lee, M, et al. (2002) Cyclooxygenase inhibitor modulation of dopaminerelated behaviours. Eur. J. Pharmacol., 450, 141-151.
139. Rothschild, A.J. (2003) Challenges in the treatment of depression with psychotic features. Biol. Psychiatry, 53, 680-690.
140. Rupniak, N.M. and Kramer, M.S. (1999) Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci., 20, 485-490.
141. Saitoh, A., Yamada, M., Yamada, M, et al. (2008) Antidepressant-like effects of the deltaopioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)- 1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res., 1208, 160-169.
142. Sanacora, G., Kendell, S.F., Levin, Y, et al. (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry, 61, 822-825.
143. Sanacora, G., Zarate, C.A., Krystal, J.H, et al. (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug. Discov., 7, 426-437
144. Schwarzer, C (2009) 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. Pharmacol. Ther., 123, 353-370.
145. Segal, M., Avital, A., Drobot, M, et al. (2007) Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients. Eur. Neuropsychopharmacol., 17, 194-198.
146. Shaltiel, G., Maeng, S., Malkesman, O, et al. (2008) Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry, 13, 858-872.
147. Shapira, N.A., Verduin, M.L., and DeGraw, J.D. (2001) Treatment of refractory major depression with tramadol monotherapy. J. Clin. Psychiatry, 62, 205-206.
148. Shirayama, Y., Ishida, H., Iwata, M, et al. (2004) Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem., 90, 1258-1268.
149. Silvestre, J.S., Nadal, R., Pallares, M, et al. (1997) Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress. Anxiety, 5, 29-33.
150. Skolnick, P., Miller, R., Young, A, et al. (1992) Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology (Berl.), 107, 489-496.
151. Song, Y., Wei, E.Q., Zhang, W.P, et al. (2004) Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport, 15, 2181-2184.
152. Spencer, C. (2000) The efficacy of intramuscular tramadol as a rapid-onset antidepressant. Aust. N. Z. J. Psychiatry, 34, 1032-1033.
153. Steinberg, R., Alonso, R., Griebel, G, et al. (2001) Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther., 299, 449-458.
154. Stoll, A.L. and Rueter, S. (1999) Treatment augmentation with opiates in severe and refractory major depression. Am. J. Psychiatry, 156, 2017.
155. Streck, E.L., Amboni, G., Scaini, G, et al. (2008) Brain creatine kinase activity in an animal model of mania. Life Sci., 82, 424-429.
156. Tejedor-Real, P., Mico, J.A., Maldonado, R, et al. (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol. Biochem. Behav., 52, 145-152.
157. Thomson, P.A., Wray, N.R., Thomson, A.M, et al. (2005) Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry, 10, 470-478.
158. Torregrossa, M.M., Jutkiewicz, E.M., Mosberg, H.I, et al. (2006) Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res., 1069, 172-181.
159. Traynor, B.J., Bruiin, L., Conwit, R, et al. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology, 67, 20-27.
160. Trullas, R. and Skolnick, P. (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol., 185, 1-10.
161. Valdez, G.R. (2009) CRF receptors as a potential target in the development of novel pharmacotherapies for depression. Curr. Pharm. Des., 15, 1587-1594.
162. Van Oekelen, D., Luyten, W.H., and Leysen, J.E. (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci., 72, 2429-2449.
163. Velentgas, P., West, W., Cannuscio, C.C, et al. (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol. Drug Saf., 15, 641-652
164. Walsh, SL., Strain, E.C., Abreu, M.E, et al. (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl.), 157, 151-162.
165. Watkins, J. and Collingridge, G. (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol. Sci., 15, 333-342.
166. Yalcin, I., Aksu, F., Bodard, S, et al. (2007) Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav. Pharmacol., 18, 623-631.
167. Yildiz, A., Guleryuz, S., Ankerst, D.P, et al. (2008) Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry, 65, 255-263.
168. Yoon, S.J., Lyoo, I.K., Haws, C, et al. (2009) Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology, 34, 1810-1818.
169. Young, A.H., Gallagher, P., Watson, S, et al. (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology, 29, 1538-1545.
170. Young, L.T., Wang, J.F., Woods, C.M, et al. (1999) Platelet protein kinase C alpha levels in drug-free and lithium-treated subjects with bipolar disorder. Neuropsychobiology, 40, 63-66.
171. Zarate, C.A., Du, J., Quiroz, J. Jr, et al. (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann. N. Y. Acad. Sci., 1003, 273-291.
172. Zarate, C.A., Payne, J.L., Quiroz, J. Jr, et al. (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry, 161, 171-174.
173. Zarate, C.A., Quiroz, J., Payne, J, et al. (2002) Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol. Bull., 36, 35-83.
174. Zarate, C.A., Jr., Quiroz, J.A., Singh, J.B, et al. (2005) An open-label trial of the glutamatemodulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry, 57, 430-432.
175. Zarate, C.A.J., Singh, J., and Manji, H.K. (2006a) Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry, 59, 1006-1020.
176. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J, et al. (2006b) A randomized trial of an N-methyl- D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 63, 856-864.
177. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J, et al. (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord., 9, 561-570.
178. Zobel, A.W., Nickel, T., Kunzel, H.E, et al. (2000) Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res., 34, 171-181